

Received
2-14-02

IN THE UNITED STATES PATENT AND TRADEMARK OFFICEIn re the Application of: **CHARI**Application No: **09/671,995**Group Art Unit: **1642**Filed: **September 29, 2000**Examiner: **S. Rawlings, Ph.D.**For: **Compositions and Methods for Treating Cancer Using
Immunoconjugates and Chemotherapeutic Agents**Docket No: **104322.198 US1**Assistant Commissioner of Patents
Washington, DC 20231

#14
(C)
2-17-02

**Supplemental Response to Restriction Requirement
As Requested By Examiner**

This Response is submitted in reply to a telephone conference with Examiner Rawlings on 13 February 2002. In that telephone conference, Examiner Rawlings requested an election of species. Applicants respectfully submit that the election of species requirement is improper as it would not cause an undue burden for the Examiner to search the entire scope of the claims. However, Applicants hereby elect, with traverse, paclitaxel as the chemotherapeutic agent, humanized monoclonal antibody N901 as the cell-binding agent, and maytansinoid as the anti-mitotic agent. In a telephone conference with Examiner Rawlings on 14 February 2002, Examiner Rawlings agreed that this election would allow for the examination of the claims.


Claims 1-7, 10-20, 28-30, 40, 41, 44, 45, 48-58, 66, 67, 70-80, and 88-89 read on the elected species. Within the elected Group II, claims 40, 41, 44, 45, 48-58, 66, 67, 70-80, and 88-89 read on the elected species.

As noted in the Response to Third Restriction Requirement, Applicants elected Group II, claims 40, 41, and 44-89, drawn to a composition and kit, with traverse. Pursuant to MPEP 821.04, Applicant respectfully requests rejoinder of Group I, claims 1-32, with elected Group II. Applicant respectfully submits that a search for the claims in Group II will necessarily encompass a search for the claims in Group I, and will not place an undue burden on the Examiner.

Applicants respectfully request examination of the application.

Requested Supplemental Response to Restriction Requirement
Application No. 09/671,995
Page 2 of 2

Respectfully submitted,



Maria L. Maebius
Registration No. 42,967

Date: February 14, 2002

Hale and Dorr LLP
1455 Pennsylvania Avenue, NW
Washington, DC 20004
Phone: 202-942-8400

FAX**HALE AND DORR LLP**
COUNSELLORS AT LAW

www.haledorr.com

THE WILLARD OFFICE BUILDING
1455 PENNSYLVANIA AVENUE N.W. • WASHINGTON, D.C. 20004-1008
202-942-8400 • FAX 202-942-8484

Total Number of Pages: 4

Fax / Phone:

To: Examiner S. Rawlings, Ph.D.
US Patent and Trademark Office

(703) 308-4426

(703) 305-3008

From: Maria L. Maebius
202-942-8452

Date: February 14, 2002

Note:

This facsimile transmission is confidential and may be privileged. If you are not the intended recipient, please immediately call the sender or, if the sender is not available, call 202-942-8333, and destroy all copies of this transmission. If the transmission is incomplete or illegible, please call the sender or, if the sender is not available, call 202-942-8333. Thank you.

Client Matter Number: 104322-198

Return To: 1009

Transmitted by: _____

BOSTON LONDON* MUNICH* NEW YORK OXFORD* PRINCETON RESTON WALTHAM WASHINGTON

Hale and Dorr LLP is a Massachusetts Limited Liability Partnership and includes Professional Corporations

* an independent joint venture law firm

WASHINGTON 165274V1

PTO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Re: U.S. Patent Application No. 09/671,995 filed September 29, 2000
Title: Compositions and Methods for Treating Cancer Using
Immunoconjugates and Chemotherapeutic Agents
Inventor: Chari
Examiner: S. Rawlings, Ph.D - Group Art Unit: 1642
Attorney Docket No.: 104322.198

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office to:

Examiner: S. Rawlings, Ph.D.
Group Art Unit: 1642
(703) 308-4426

on February 14, 2002
Date


Signature

Maria L. Maebius, Reg. No. 42,967
Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Document

**Supplemental Response to Restriction Requirement
As Requested by Examiner**

No.
Pgs.
2

**Total Number of Pages attached (excluding this
Certificate of Transmission)**

2

Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case.
Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark
Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents,
Washington, DC 20231.